Comparison · NCT00383019-e3ef396f
KP2035 Group vs Xalatan Group: Number of Subjects With an IOP of <=17 mmHg at Week 8
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. KP2035 Group vs Xalatan Group: Number of Subjects With an IOP of <=17 mmHg at Week 8. Trial comparisons, record NCT00383019-e3ef396f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00383019-e3ef396f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.576 | 0.495 | 0.654 | wilson | |
| Risk in group 2 | 0.414 | 0.337 | 0.495 | wilson | |
| Risk difference, group 1 minus group 2 | 0.163 | 0.0473 | 0.272 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.39 | 1.1 | 1.77 | log | |
| Odds ratio, group 1 over group 2 | 1.93 | 1.21 | 3.08 | log | |
| Number needed to treat, for one more participant with the outcome on KP2035 Group than on Xalatan Group | 6.15 | 3.68 | 21.1 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | KP2035 Group | Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00). | 83 | 144 | OG000 |
| Group 2 | Xalatan Group | Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00). | 60 | 145 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects With an IOP of <=17 mmHg at Week 8
- Description
- Number of subjects who achieved IOP reduction to 17 mmHg or below at Week 8
- Time frame
- Week 8
- Population
- The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.
Source ClinicalTrials.gov
Trial
- Title
- A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).
- NCT number
- NCT00383019
- Phases
- PHASE3
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- Xalatan, Xalacom
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Results first posted
- 2009-05-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00383019?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00383019-e3ef396f